MedWatch is the Food and Drug Administration’s (FDA) safety information and adverse event reporting program. It serves as a centralized system for healthcare professionals, patients, and consumers to report serious problems with medical products, including drugs, medical devices, and dietary supplements.
The program collects and analyzes these reports to identify potential safety issues and take appropriate action to protect public health. MedWatch also disseminates important safety information to healthcare providers and the public through various channels, including safety alerts and newsletters.
MedWatch plays a crucial role in clinical research by providing a standardized system for reporting adverse events and safety concerns. This centralized reporting mechanism allows researchers to monitor and evaluate the safety profiles of investigational drugs and medical devices throughout the clinical trial process and post-market surveillance.
The data collected through MedWatch can inform study protocols, help identify potential risks, and guide decision-making in clinical trials. Furthermore, MedWatch reports can contribute to the overall assessment of a product’s benefit-risk profile, which is essential for regulatory approvals and ongoing safety evaluations in clinical research.
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
Copyright @ 2026 Axcellant